Latest Oncology News

Survival Benefit Found With Abiraterone/Prednisolone-Based Combos in High-Risk Nonmetastatic Prostate Cancer

Survival Benefit Found With Abiraterone/Prednisolone-Based Combos in High-Risk Nonmetastatic Prostate Cancer

September 19th 2021

Matthew Fowler

When added to androgen-deprivation therapy, abiraterone acetate and prednisolone with or without enzalutamide for 2 years improved survival outcomes in men with high-risk nonmetastatic prostate cancer.

Prednisone Added to ADT Plus Docetaxel Improves Radiographic PFS and OS in mCSPC

Prednisone Added to ADT Plus Docetaxel Improves Radiographic PFS and OS in mCSPC

September 19th 2021

Jamie Cesanek

Prednisone added to androgen-deprivation therapy plus docetaxel improved radiographic progression-free survival and overall survival in patients with de novo metastatic castration-sensitive prostate cancer.

Novel Therapy Appears Safe, Effective in Metastatic Castration Resistant Prostate Cancer

Novel Therapy Appears Safe, Effective in Metastatic Castration Resistant Prostate Cancer

September 19th 2021

Colleen Moretti

Sabizabulin was well tolerated and associated with significant and durable objective tumor responses in patients with metastatic castration resistant prostate cancer.

Nivolumab-Rucaparib Combo Induces Clinically Effective Outcomes in Subgroup of Patients with mCRPC

Nivolumab-Rucaparib Combo Induces Clinically Effective Outcomes in Subgroup of Patients with mCRPC

September 19th 2021

Ryan McDonald

A group of patients with metastatic castration resistant prostate cancer achieved favorable outcomes after receiving treatment with nivolumab in combination with rucaparib.

Switch to Darolutamide Maintenance Improves Survival in Taxane and NHA Pretreated mCRPC

Switch to Darolutamide Maintenance Improves Survival in Taxane and NHA Pretreated mCRPC

September 19th 2021

Nichole Tucker

Switching maintenance to darolutamide following taxane-based therapy with at least 1 novel hormonal agent showed statistically significant but clinically modest improvement in radiographic progression-free survival and event-free survival in patents with metastatic castration-resistant prostate cancer.

Latest Oncology Videos

All Oncology News

UGN-101 Induction Produces Durable Responses in Low-Grade Upper Tract Urothelial Carcinoma

September 13th 2021

Kristi Rosa

Treatment with the mitomycin-containing reverse thermal gel UGN-101 resulted in a lengthy period of durable response when administered as induction treatment in patients with low-grade upper tract urothelial carcinoma.

Novel Neoadjuvant Triplet Shows Preliminary Promise in Resectable Pleural Mesothelioma

September 13th 2021

Lindsay Fischer

Neoadjuvant treatment with cisplatin/pemetrexed plus atezolizumab, followed by maintenance atezolizumab, demonstrated early efficacy with acceptable safety in patients with resectable pleural mesothelioma.

Yoga Possesses Potential to Improve QoL, Immune Responses, and Inflammation in Prostate Cancer

September 13th 2021

Colleen Moretti

Improvements in quality of life, antitumor immune responses, and inflammation could be resulting benefits of the incorporation of regular yoga practice in the lives of men with prostate cancer who are undergoing prostatectomy.

MRgFUS Improved Sexual Function, Urinary Continence in Men with Intermediate-Risk Prostate Cancer

September 13th 2021

Jason Harris

Magnetic resonance-guided focused ultrasound focal therapy delivered to the index lesion produced better outcomes for men with intermediate-risk prostate cancer compared with radical prostatectomy or radiation therapy.

18F-DCFPyL Could Become a Key Diagnostic Tool for Biochemical Recurrence in Prostate Cancer

September 13th 2021

Kristie L. Kahl

18F-DCFPyL, a PET prostate specific membrane antigen targeting agent, demonstrated statistically significant potential in detecting biochemical recurrence in men with prostate cancer.

Panvac Plus BCG Does Not Significantly Delay Recurrence in Advanced NMIBC

September 13th 2021

Brittany Lovely

The addition of a recombinant pox-viral vector vaccine Panvac™ to bacillus Calmette-Guérin did not significantly improve clinical outcomes for patients with BCG-unresponsive non–muscle invasive bladder cancer.

FDA Accepts BLA for Tislelizumab in Esophageal Squamous Cell Carcinoma

September 13th 2021

Kristi Rosa

The FDA has accepted for review a biologics license application for tislelizumab as a potential therapeutic option in patients with unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma following previous systemic therapy.

Loaiza-Bonilla Offers Guidance on Optimizing Treatment Selection in Pancreatic Cancer

September 13th 2021

OncLive Staff

Dr. Loaiza-Bonilla discusses approaches to frontline treatment selection in metastatic pancreatic cancer, the effects of adverse effects and toxicities in treatment planning, and treatment options available to patients post gemcitabine-based regimens.

Mobocertinib Elicits Antitumor Activity in EGFR Exon 20 Insertion+ NSCLC After Disease Control With EGFR TKIs

September 13th 2021

Ariana Pelosci

Mobocertinib was found to provide a meaningful clinical benefit with acceptable tolerability in patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer who had previously achieved disease control of 6 months or longer with EGFR TKIs.

Mobocertinib Plus T-DM1 Elicits Preclinical Activity in HER2 Exon 20 Insertion+ Lung Cancer Models

September 13th 2021

Ariana Pelosci

Mobocertinib plus ado-trastuzumab emtansine demonstrated inhibitory effects in HER2 exon 20 insertion–mutated lung cancer cell lines.

Masitinib Plus Docetaxel Produces PFS Benefit in mCRPC With Low Metastatic Involvement

September 13th 2021

Jessica Hergert

The investigational small molecule masitinib plus docetaxel resulted in a statistically significant 21% reduction in the risk of progression or death compared with placebo plus docetaxel in men with metastatic castration-resistant prostate cancer and baseline alkaline phosphatase levels of 250 IU/mL or less.

Avelumab Plus BCG Induction Shows Favorable Tolerability in BCG-Unresponsive NMIBC

September 13th 2021

Kristie L. Kahl

The addition of avelumab to Bacillus Calmette-Guerin induction therapy appeared to be safe and well tolerated in patients with BCG-unresponsive non–muscle invasive bladder cancer.

Systemic Review Underscores Need for Smoking Status Data on Genitourinary Cancer Trials

September 13th 2021

Colleen Moretti

Smoking status is not often reported on genitourinary cancer clinical trials, which limits understanding of how smoking impacts the treatment, survival, and quality of life of this patient population.

Monitoring Treatment Response in MF

September 13th 2021

Srdan Verstovsek, MD, PhD, MD Anderson Cancer Center

Hematology/oncology experts review their approach to monitoring treatment response in myelofibrosis (MF) and when they would consider switching therapies.

Oral GnRH Antagonist Therapy for mCSPC

September 13th 2021

Alicia K. Morgans, MD, MPH, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Implications of treating patients with metastatic castration-sensitive prostate cancer with relugolix, an oral GnRH antagonist.

See All News